heterogeneity was considered low, moderate, substantial, or considerable for estimated I 2 value of 040%, 3060%, 5090%, and 75100%, respectively
Natural S-equol decreases bone resorption in postmenopausal, non-equol-producing Japanese women: a pilot randomized, placebo-controlled trial
Related Content KRAS G12D inhibitors continue to advance, but treatment resistance remains an important challenge
Is Trulicity the same as Rybelsus
The difference is how the product is built
The Global GLP-1 Revolution and Its Price Tag In less than a decade, GLP-1 drugs (medicines that mimic a natural gut hormone to help control blood sugar and appetite) have moved from niche diabetes treatments to global blockbusters for diabetes, obesity, and heart protection